Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CES2 | O00748 | 2/20 | 0.58 |
| ▸ | CES1 | P23141 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159419 | 1.00 | LMNA (0.65) | LMNAMAPK1CES2CES1HPGD | |
| SCHEMBL4026125 | 1.00 | LMNA (0.65) | LMNAMAPK1CES2CES1HPGD | |
| Hydrochloric Acid SCHEMBL8893721 | 0.98 | LMNA (0.62) | LMNAMAPK1CES2CES1HPGD | |
| Water SCHEMBL28741444 | 0.98 | LMNA (0.62) | LMNAMAPK1CES2CES1HPGD | |
| Benzoic Acid SCHEMBL4776749 | 0.89 | LMNA (0.59) | LMNAMAPK1CES2CES1HPGD | |
| Butane SCHEMBL8389531 | 0.89 | LMNA (0.54) | LMNAMAPK1CES2CES1HPGD | |
| SCHEMBL9015288 | 0.87 | PTGS2 (0.52) | LMNAMAPK1CES2CES1 | |
| Mandelic Acid SCHEMBL11083521 | 0.83 | LMNA (0.86) | LMNAMAPK1CES2CES1HPGD | |
| Mandelic Acid SCHEMBL8876737 | 0.80 | LMNA (0.90) | LMNAMAPK1CES2CES1HPGD | |
| Mandelic Acid SCHEMBL6056301 | 0.80 | LMNA (0.90) | LMNAMAPK1CES2CES1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | claimed |
| EP-3490986-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-24 | — | — | EP | claimed |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-08-25 | — | — | US | claimed |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2019-06-06 | — | — | US | claimed |
| EP-3490986-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2019-06-05 | — | — | EP | claimed |
| WO-2018019929-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-02-01 | — | — | WO | claimed |
| CN-105294479-B | A kind of 3R amino replaces the preparation method of butanamide derivatives | 新发药业有限公司 | 2017-09-22 | — | — | CN | claimed |
| CN-120843487-A | Nitrilase mutant with high stereoselectivity and hydration activity and application thereof | 浙江工业大学 | 2025-10-28 | — | — | CN | disclosed |
| CN-117405791-B | Construction method and quality detection method of fingerprint of lung-heat-clearing decoction compound preparation | 江西药都樟树制药有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-117405791-A | Construction method and quality detection method of fingerprint of lung-heat-clearing decoction compound preparation | 江西药都樟树制药有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2023012205-A1 | SYNTHESIS OF SPECIFIC BUTYRATE COMPOUNDS | DSM IP ASSETS B.V. (NL) | 2023-02-09 | — | — | WO | disclosed |
| CN-110563717-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | disclosed |
| WO-2005108393-A1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-17 | — | — | WO | disclosed |
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES | 2004-12-16 | — | — | US | disclosed |
| WO-2004076424-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-10 | — | — | WO | disclosed |
| EP-0323807-A2 | Certain 2-substituted adenosine derivatives | CIBA-GEIGY AG (CH) | 1989-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254159-A1 | Heterocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | LMNA 2735/4885MAPK1 72/4885CES2 2305/4885 |
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | CNR1, CNR2, GPR18 | LMNA 3703/4885MAPK1 1200/4885CES2 623/4885 |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | LMNA 4841/4885MAPK1 1111/4885CES2 2785/4885 |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | LMNA 4841/4885MAPK1 1111/4885CES2 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.